Abstract:Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component. However, there is a relative paucity of guidance on the management of this heterogeneous group of diseases. In ILDs other than IPF, immunosuppression is the cornerstone of therapy, with varying levels of evidence for different immunomodulatory agents and for each specific ILD. Classification of ILDs is important for guiding treatment decisions. Immunomodulatory agents mainly include corticosteroids, mycophenolate mofetil (MMF), azathioprine, methotrexate, cyclophosphamide and rituximab. In this review, the available evidence for single agents in the most common ILDs is first discussed. We then reviewed practical therapeutic approaches in connective tissue disease–related ILD and interstitial pneumonia with autoimmune features, scleroderma-related ILD, vasculitis and dermatomyositis with hypoxemic respiratory failure, idiopathic non-specific interstitial pneumonia, hypersensitivity pneumonitis sarcoidosis, fibrosing organizing pneumonia and eosinophilic pneumonia. The treatment of acute exacerbations of ILD is also discussed. Therapy augmentation in ILD is dictated by the recognition of progression of disease. Criteria for the evaluation of progression of disease are then discussed. Finally, specific protocol and measures to increase patients’ safety are reviewed as well, including general monitoring and serologic surveillance, Pneumocystis jirovecii prophylaxis, patients’ education, genetic testing for azathioprine, MMF serum levels and cyclophosphamide administration protocols. Immunomodulatory therapies are largely successful in the management of ILDs and can be safely managed with the application of specific protocols, precautions and monitoring.

Updated treatment on interstitial lung diseases

Interstitial lung disease revisited

Advance in treatment of interstitial lung disease

Current status of research on interstitial lung disease complicated with lung cancer

Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment

Immunomodulatory treatment of interstitial lung disease

Cancer therapy-related interstitial lung disease

Recent Advancement of Interstitial Lung Disease in Molecular Genetics

New insights into the treatment of CTD-ILD

[A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease].

Interstitial lung disease in rheumatic diseases: an update of the 2018 review

Current Challenges and Novel Therapeutic Perspectives

Interstitial lung abnormalities: What do we know and how do we manage?

Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

Progress in the treatment of secondary interstitial lung disease in patients with connective tissue disease

The advances on interstitial lung disease associated with molecular targeted drugs

Clinical analysis of 21 patients with interstitial lung disease complicated with lung cancer

Progress in the diagnosis and treatment of connective tissue disease-associated interstitial lung disease in children

Research Progress in pathogenesis of connective tissue disease-associated interstitial lung disease from the perspective of pulmonary cells

Complications of fibrotic interstitial lung disease for the general radiologist

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players